Compugen (CGEN) Non-Current Deffered Revenue (2013 - 2026)
Compugen (CGEN) reported Non-Current Deffered Revenue of $22.1 million for Q1 2026, down 30.31% on a YoY basis from $31.8 million in Q1 2025, and down 11.24% sequentially from $24.9 million in Q4 2025.
Compugen (CGEN) Non-Current Deffered Revenue (2013 - 2026) Analysis & Trends
Compugen (CGEN) has 5 years of Non-Current Deffered Revenue data on file, last reported at $22.1 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Deffered Revenue fell 30.31% year-over-year to $22.1 million; the trailing twelve-month figure through Mar 2026 stood at $22.1 million (down 30.31% YoY), and the FY2025 full-year result was $24.9 million, down 26.74% from the prior year.
- Non-Current Deffered Revenue retreated to $22.1 million in Q1 2026, from $24.9 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $34.0 million in Q4 2024 to a low of $21.0 million in Q2 2024.
- A 4-year average of $26.9 million and a median of $26.5 million in 2023 frame the typical range for Non-Current Deffered Revenue.
- Across the five-year window, Non-Current Deffered Revenue jumped 40.73% in 2025 and plunged 30.31% in 2026, its largest moves.
- Tracing CGEN's Non-Current Deffered Revenue over 4 years: stood at $25.4 million in 2023, then surged by 34.08% to $34.0 million in 2024, then declined by 26.74% to $24.9 million in 2025, then fell by 11.24% to $22.1 million in 2026.
- Business Quant data shows CGEN's Non-Current Deffered Revenue at $22.1 million in Q1 2026, $24.9 million in Q4 2025, and $27.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Compugen | 221.26 Mn | 129.51 Mn | 352,000.00 | 22.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.14 Mn |
| Dec 31, 2025 | 24.94 Mn |
| Sep 30, 2025 | 27.57 Mn |
| Jun 30, 2025 | 29.59 Mn |
| Mar 31, 2025 | 31.77 Mn |
| Dec 31, 2024 | 34.05 Mn |
| Sep 30, 2024 | 29.24 Mn |
| Jun 30, 2024 | 21.03 Mn |
| Mar 31, 2024 | 23.23 Mn |
| Dec 31, 2023 | 25.39 Mn |
| Dec 31, 2013 | 1.45 Mn |